Research Insight
Research Insight
Queen’s University leading clinical trial on cell therapy treatment for COVID19 patients
Researchers at Queen’s University Belfast are leading a UK-wide clinical trial, offering an innovative cell therapy treatment for COVID-19 patients with acute respiratory failure.
This clinical...
News
Oxford University Imaging Lab and Zegami comes together to target Cardiovascular disease
Zegami, the data visualisation company, has been appointed by Oxford University researchers at the Oxford Cardiovascular Clinical Research Facility to accelerate research into cardiovascular disease.
The...
Research Insight
What Drugs Do with a Brain?
The brain is a complex body organ. It comprises a three-pound white and gray matter mass that is at the center of human activity. Essentially,...
Research Insight
Mount Sinai Discovers New Drug Combo to Induce High Rates of Human Beta Cell Regeneration
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a novel combination of two classes of drugs that, together, cause the highest...
Research Insight
Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found that treating soft tissue sarcoma with radiation over a significantly shorter...
Research Insight
Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohns Disease
Takeda Pharmaceutical Company Limited announced results from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation...
Research Insight
Imminence of New Gonorrhea Therapeutic Drugs is Evident as the Bacteria Grow Super Resistant to Antibiotics
According to a new study, the gonorrhea therapeutics market will reach US$ 970 Mn in 2019, and estimated to register a 4% Y-o-Y over 2018....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
